Revenue and EBITDA Growth
IRIDEX reported revenue of $11.9 million for Q1 2025, a slight increase from $11.8 million in Q1 2024. Achieved positive adjusted EBITDA of $0.4 million, an improvement of $2.9 million compared to the prior year quarter.
Cost Reduction and Profitability
Operating expenses decreased by $2.5 million to $5.3 million in Q1 2025 from $7.8 million in Q1 2024, driven by workforce reductions and lower discretionary spending, resulting in improved profitability.
Strategic Investment and Balance Sheet Strengthening
Received a $10 million strategic investment from Novel Inspiration, which strengthened the balance sheet and helped settle the Lind note payable.
Product Performance in Glaucoma Segment
Cyclo G6 product family revenue grew 8% year-over-year, primarily driven by higher probe sales, with MP3 probe unit sales exceeding expectations.
International Market Growth
Strong sales in EMEA and Asia, with regulatory approvals driving capital equipment sales. Medical retina sales in China showed a healthy recovery.